Nanobiotix Reports Promising Phase 2 Data for JNJ-1900 (NBTXR3) in Inoperable Lung Cancer

summarizeSummary

Nanobiotix announced promising initial Phase 2 clinical trial data for its nanoradioenhancer JNJ-1900 (NBTXR3) in stage 3 inoperable lung cancer, showing favorable safety and efficacy compared to benchmarks.

check_boxKey Events

• Phase 2 Data Presented

  First data from the randomized Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3) in Stage 3 inoperable non-small cell lung cancer was presented by Johnson & Johnson at the 2026 European Lung Cancer Conference.

• Promising Efficacy Results

  Initial efficacy responses in 7 patients showed an Overall Response Rate (ORR) of 71.4% and a Disease Control Rate (DCR) of 100%, which is promising relative to the estimated benchmark ORR of 45%-50%.

• Favorable Safety Profile

  The procedure demonstrated an acceptable safety profile without serious treatment-emergent adverse events (TEAEs) and did not adversely impact patients' ability to continue planned therapy.

auto_awesomeAnalysis

This filing reports positive initial data from a randomized Phase 2 trial for JNJ-1900 (NBTXR3) in a challenging indication, stage 3 inoperable non-small cell lung cancer. The acceptable safety profile and promising efficacy, with an Overall Response Rate (ORR) of 71.4% significantly exceeding the 45-50% benchmark, represent a material de-risking event for the program. The data, presented by partner Johnson & Johnson, reinforces the potential of this nanoradioenhancer and supports its broader development strategy, including the ongoing Phase 3 study in head and neck cancers.